Abstract
BackgroundAntibody-drug conjugates (ADCs) have emerged as an effective and safe anticancer therapy. ADCs may induce immunogenic cell death (ICD) that promotes additional endogenous antitumor immune responses. We have identified GPC2...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have